Therapeutics Startups

Intact Therapeutics develops next-generation biopharmaceutical therapies for gastrointestinal diseases to address unmet clinical needs. The company is clinical-stage and focused on improving patient outcomes through innovative medicines.

2 investors

Adventris is a biotechnology company developing cancer immunotherapy treatments.

1 investor

Andson Biotech develops analytical tools for the analysis of biotherapeutics, aimed at supporting the discovery and development of biologic drugs.

1 investor

Cisterna Biologics develops yeast-engineered mRNA manufacturing technology that can be selectively purified to drive protein expression in human cells. The company targets cost-effective, scalable, and non-immunogenic mRNA production for therapeutic applications.

1 investor

EncepHeal develops small-molecule medications targeting the dopamine transporter to treat stimulant addiction, including cocaine and methamphetamine, for which no FDA-approved treatments currently exist. The company uses allosteric modulators designed to reduce drug cravings without the addictive potential of earlier dopamine-targeting approaches.

1 investor

Eris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.

1 investor

Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

1 investor

Evolvere BioSciences develops antibiotics using computational models and evolutionary data to target pathogenic bacteria while preserving beneficial microbes, designed to resist the development of bacterial resistance.

1 investor

Exin Therapeutics develops an AI-guided drug discovery platform that uses experimental mouse studies to identify neurological therapies, starting with epilepsies linked to autism and Parkinson's disease. The company trains machine learning models on proprietary multimodal neuroscience data to guide its therapeutic screening process.

1 investor

Guardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.

1 investor

KemNet provides modified versions of existing pharmaceuticals to pharmacies, tailored for specific patient populations with altered formulations that aim for improved efficacy across indications including sexual dysfunction, hair loss, pain management, weight reduction, and women's health.

1 investor

Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.

1 investor

Macromoltek provides computational modeling and AI-driven antibody design services to biotech and pharmaceutical companies, accelerating the discovery and optimization of therapeutic antibodies. The platform reduces time-to-market and increases the probability of clinical success in drug development.

1 investor

Matrubials develops antimicrobial peptides derived from milk to create novel therapeutics for bacterial infections, starting with bacterial vaginosis. The company uses AI-enabled technology to identify and validate bioactive molecules for infectious disease treatments.

1 investor

Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.

1 investor

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

1 investor

Relevium Medical is a biopharmaceutical company developing long-lasting treatments for chronic pain conditions, particularly osteoarthritis. The company focuses on therapeutic hydrogels and drug discovery for patients with debilitating pain.

1 investor

RonanRx offers personalized GLP-1 weight-management care delivered via text, where a licensed physician reviews a patient's history to set an individualized dose, titration schedule, and patient-specific adjunct, and a licensed pharmacist at the patient's selected pharmacy verifies and releases compounded, patient-specific prescriptions. It serves individual patients in the US (availability varies by state) and plans to add hormone therapy (HRT).

1 investor

SafeBeat uses engineering and machine learning to develop solutions for cardiac care and arrhythmia management. The company serves cardiologists, electrophysiologists, and healthcare organizations.

1 investor

SynsoryBio develops protein-based drugs that detect their location in the body and activate only at diseased tissue, with applications across cancer and autoimmune conditions.

1 investor